Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Respiratory, and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CYSLTR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CYSLTR1 Recombinant Protein Sequence Verified. Theoretical MW. High Purity (>95%). Designed for structural studies and antibody screening. |
View CYSLTR1 Products |
| Gene Delivery | CYSLTR1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Crucial for cell-based functional assays. |
View CYSLTR1 Products |
| Benchmark Ab | Anti-CYSLTR1 Biosimilar Recombinant positive control antibody for validation and assay setup. |
View CYSLTR1 Products |
| Validator | CYSLTR1 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View CYSLTR1 Products |
| Related Target A | CYSLTR2 Homologous receptor. Essential for off-target counter-screening to ensure selectivity. |
View CYSLTR2 Products |
| Related Target B | ALOX5 5-Lipoxygenase, the upstream enzyme in the cysteinyl leukotriene synthesis pathway. |
View ALOX5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent GPCR screening | Lentivirus for stable cell line generation. Cell-based assays preserve the native 7-transmembrane conformation. |
| Subfamily off-target cross-reactivity | CYSLTR2 recombinant proteins and stable cell lines available for strict selectivity counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CYSLTR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CYSLTR1 therapeutics is intensifying, with major players shifting focus from traditional small-molecule antagonists to highly selective biologics and novel combination therapies. As first-generation therapies (such as Montelukast) reach mature market status, the next wave of R&andD is targeting precision oncology applications, neuroinflammatory diseases, and severe refractory asthma where dual-receptor targeting or highly specific monoclonal antibodies are required.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Merck, Ono Pharmaceutical | Asthma, Allergic Rhinitis | Selectivity Assay (Need CYSLTR1 vs CYSLTR2 stable cell lines) |
| Monoclonal Antibodies | Academic Institutes, Biotech Startups | Colorectal Cancer, Glioblastoma | Conformation preservation (Need Lentivirus for Stable Cell Line) |
| Combination Therapies | Global Pharma Consortia | Severe Inflammatory Diseases | Pathway Validation (Need ALOX5 / CYSLTR1 dual knockdowns) |